Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Tirzepatide is a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist that is under development for the treatment of type 2 diabetes. The efficacy and safety of once-weekly tirzepatide as compared with semaglutide, a selective GLP-1 receptor agonist, are unknown. METHODS: In an open-label, 40-week, phase 3 trial, we randomly assigned 1879 patients, in a 1:1:1:1 ratio, to receive tirzepatide at a dose of 5 mg, 10 mg, or 15 mg or semaglutide at a dose of 1 mg. At baseline, the mean glycated hemoglobin level was 8.28%, the mean age 56.6 years, and the mean weight 93.7 kg. The primary end point was the change in the glycated hemoglobin level from baseline to 40 weeks. RESULTS: The estimated mean change from baseline in the glycated hemoglobin level was -2.01 percentage points, -2.24 percentage points, and -2.30 percentage points with 5 mg, 10 mg, and 15 mg of tirzepatide, respectively, and -1.86 percentage points with semaglutide; the estimated differences between the 5-mg, 10-mg, and 15-mg tirzepatide groups and the semaglutide group were -0.15 percentage points (95% confidence interval [CI], -0.28 to -0.03; P = 0.02), -0.39 percentage points (95% CI, -0.51 to -0.26; P<0.001), and -0.45 percentage points (95% CI, -0.57 to -0.32; P<0.001), respectively. Tirzepatide at all doses was noninferior and superior to semaglutide. Reductions in body weight were greater with tirzepatide than with semaglutide (least-squares mean estimated treatment difference, -1.9 kg, -3.6 kg, and -5.5 kg, respectively; P<0.001 for all comparisons). The most common adverse events were gastrointestinal and were primarily mild to moderate in severity in the tirzepatide and semaglutide groups (nausea, 17 to 22% and 18%; diarrhea, 13 to 16% and 12%; and vomiting, 6 to 10% and 8%, respectively). Of the patients who received tirzepatide, hypoglycemia (blood glucose level, <54 mg per deciliter) was reported in 0.6% (5-mg group), 0.2% (10-mg group), and 1.7% (15-mg group); hypoglycemia was reported in 0.4% of those who received semaglutide. Serious adverse events were reported in 5 to 7% of the patients who received tirzepatide and in 3% of those who received semaglutide. CONCLUSIONS: In patients with type 2 diabetes, tirzepatide was noninferior and superior to semaglutide with respect to the mean change in the glycated hemoglobin level from baseline to 40 weeks. (Funded by Eli Lilly; SURPASS-2 ClinicalTrials.gov number, NCT03987919.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
Multiple Imputation for Nonresponse in Surveys
Rubin, D. B. (1987) · Wiley Series in Probability and Statistics · doi:10.1002/9780470316696 · Cited by 20,701
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Self-citationDavies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Self-citationGlucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419
Self-citationCoskun, T., Sloop, K. W., Loghin, C., Alsina-Fernandez, J., Urva, S., Bokvist, K. B., Cui, X., Briere, D. A., Cabrera, O., Roell, W. C., et al. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.09.009 · Cited by 882
Self-citationFrias, J. P., Nauck, M. A., Van, J., Kutner, M. E., Cui, X., Benson, C., Urva, S., Gimeno, R. E., Milicevic, Z., Robins, D., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32260-8 · Cited by 815
Self-citationPratley, R. E., Aroda, V. R., Lingvay, I., Lüdemann, J., Andreassen, C., Navarria, A., & Viljoen, A. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30024-x · Cited by 790
Sorli, C., Harashima, S.-I., Tsoukas, G. M., Unger, J., Karsbøl, J. D., Hansen, T., & Bain, S. C. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30013-x · Cited by 745
Ahmann, A. J., Capehorn, M., Charpentier, G., Dotta, F., Henkel, E., Lingvay, I., Holst, A. G., Annett, M. P., & Aroda, V. R. (2018) · Diabetes Care · doi:10.2337/dc17-0417 · Cited by 596
Cited by
Items 101–200 of 2,039
Polycystic Ovary Syndrome: Pathophysiology and Therapeutic Opportunities
Dong, J., & Rees, D. A. (2023) · BMJ Medicine · doi:10.1136/bmjmed-2023-000548 · Cited by 123
“…analogues, such as semaglutide or dulaglu-tide, 139 140 or dual GLP- 1-glucose dependent insuli-notropic polypeptide agonists, such as tirzepatide, 141 could provide more therapeutic opportunities, with the potential benefits of greater effects on weight loss, longer duration of action, and…”
The incretin co-agonist tirzepatide requires GIPR for hormone secretion from human islets
El, K., Douros, J. D., Willard, F. S., Novikoff, A., Sargsyan, A., Perez-Tilve, D., Wainscott, D. B., Yang, B., Chen, A., Wothe, D., et al. (2023) · Nature Metabolism · doi:10.1038/s42255-023-00811-0 · Cited by 118
“05 nM radioligand (Human/Mouse [125I] GLP-1(7-36)NH2 and Human [125I]GIP(1-42)OH; both PerkinElmer >2,200 Ci mmol, >95% purity) was added to peptide in 100 μl assay buffer (concentration–response curves in DMSO, final concentration of 0.”
BackgroundMethodInfluentialTirzepatide for the treatment of adults with type 2 diabetes: An endocrine perspective
De Block, C., Bailey, C., Wysham, C., Hemmingway, A., Allen, S. E., & Peleshok, J. (2023) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14831 · Cited by 121
“52% (63-70 mmol/mmol).(56,73-76) In all five studies, tirzepatide was associated with mean reductions from baseline in HbA1c ranging”
BackgroundMethodInfluentialObesity‐related glomerulopathy: Current approaches and future perspectives
Martínez‐Montoro, J. I., Morales, E., Cornejo-Pareja, I. M., Tinahones, F. J., & Fernández‐García, J. C. (2022) · Obesity Reviews · doi:10.1111/obr.13450 · Cited by 145
“therapeutic options for patients with ORG, but devoted clinical trials are needed.(144,145)”
BackgroundSun, Q., Xing, X., Wang, H., Wan, K., Fan, R., Liu, C., Wang, Y., Wu, W., Wang, Y., & Wang, R. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115586 · Cited by 140
Obesity and cardiovascular disease: an ESC clinical consensus statement
Koskinas, K. C., Craenenbroeck, E. M. V., Antoniades, C. A., Blüher, M., Gorter, T. M., Hanssen, H., Marx, N., McDonagh, T. A., Mingrone, G., Rosengren, A., et al. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae279 · Cited by 148
Tirzepatide: A Systematic Update
Forzano, I., Varzideh, F., Avvisato, R., Jankauskas, S. S., Mone, P., & Santulli, G. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232314631 · Cited by 118
Linz, D., Andrade, J. G., Arbelo, E., Boriani, G., BREITHARDT, G. E., Camm, A. J., Caso, V., Nielsen, J. C., Melis, M. D., Potter, T. J. R. D., et al. (2024) · EP Europace · doi:10.1093/europace/euae070 · Cited by 129
Luna-Marco, C., Iannantuoni, F., Hermo-Argibay, A., Devos, D., Salazar, J. D., Víctor, V. M., & Rovira-Llopis, S. (2024) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2024.01.015 · Cited by 114
Pirro, V., Roth, K. D., Lin, Y., Willency, J. A., Milligan, P. L., Wilson, J. M., Ruotolo, G., Haupt, A., Newgard, C. B., & Duffin, K. L. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab722 · Cited by 113
Ansari, H. U. H., Qazi, S. U., Sajid, F., Altaf, Z., Ghazanfar, S., Naveed, N., Ashfaq, A. S., Siddiqui, A. H., Iqbal, H., & Qazi, S. (2024) · Endocrine Practice · doi:10.1016/j.eprac.2023.11.007 · Cited by 112
Prevention of cardiorenal damage: importance of albuminuria
Ruilope, L. M., Ortíz, A., Lucía, A., Miranda, B., Álvarez‐Llamas, G., Barderas, M. G., Volpe, M., Ruiz‐Hurtado, G., & Pitt, B. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac683 · Cited by 125
Liskiewicz, A., Khalil, A., Liskiewicz, D., Novikoff, A., Grandl, G., Maity-Kumar, G., Gutgesell, R. M., Bakhti, M., Bastidas-Ponce, A., Czarnecki, O., et al. (2023) · Nature Metabolism · doi:10.1038/s42255-023-00931-7 · Cited by 110
“But although GIPR–GLP-1R co-agonism decreases body weight with superior efficacy relative to GLP-1R agonism alone in preclinical 1–3 and clinical studies 4,5 , the role of GIP in regulating energy metabolism remains enigmatic.”
BackgroundNew horizons. A new paradigm for treating to target with second-generation obesity medications
Garvey, W. T. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab848 · Cited by 110
Sibony, R. W., Segev, O., Dor, S., & Raz, I. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242417147 · Cited by 167
“[69].”
Glucagon‐like peptide agonists: A prospective review
Mariam, Z., & Niazi, S. K. (2023) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.462 · Cited by 130
“58 The study found that tirzepatide was superior to semaglutide regarding the mean change in glycated haemoglobin level.”
BackgroundAdverse Events Related to Tirzepatide
Mishra, R., Raj, R., Elshimy, G., Zapata, I., Kannan, L., Majety, P., Edem, D., & Correa, R. (2023) · Journal of the Endocrine Society · doi:10.1210/jendso/bvad016 · Cited by 110
The past, present, and future physiology and pharmacology of glucagon
Capozzi, M. E., D’Alessio, D. A., & Campbell, J. E. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.10.001 · Cited by 109
Approach to Obesity Treatment in Primary Care: A Review
Yanovski, S. Z., & Yanovski, J. A. (2024) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2023.8526 · Cited by 103
Nauck, M. A., Tuttle, K. R., Tschöp, M. H., & Blüher, M. (2026) · The Lancet · doi:10.1016/s0140-6736(25)02105-1 · Cited by 123
Karagiannis, T., Malandris, K., Avgerinos, I., Stamati, A., Kakotrichi, P., Liakos, A., Vasilakou, D., Kakaletsis, N., Tsapas, A., & Bekiari, E. (2024) · Diabetologia · doi:10.1007/s00125-024-06144-1 · Cited by 102
“However, direct comparison between s.c. tirzepatide and s.c. semaglutide in RCTs is scarce [6, 7], presenting a challenge in drawing robust and precise conclusions regarding their comparative efficacy.”
The promise of new anti-obesity therapies arising from knowledge of genetic obesity traits
Hinney, A., Körner, A., & Fischer-Posovszky, P. (2022) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00716-0 · Cited by 101
Gao, L., Lee, B. W., Chawla, M., Kim, J., Huo, L., Du, L., Huang, Y., & Ji, L. (2023) · Nature Medicine · doi:10.1038/s41591-023-02344-1 · Cited by 104
Sarcopenia and Diabetes: A Detrimental Liaison of Advancing Age
Lisco, G., Disoteo, O. E., De Tullio, A., De Geronimo, V., Giagulli, V. A., Monzani, F., Jirillo, E., Cozzi, R., Guastamacchia, E., De Pergola, G., et al. (2023) · Nutrients · doi:10.3390/nu16010063 · Cited by 101
Lombardi, L., Genio, V. D., Alberício, F., & Williams, D. R. (2025) · Chemical Reviews · doi:10.1021/acs.chemrev.4c00989 · Cited by 146
GLP1 Receptor Agonists—Effects beyond Obesity and Diabetes
Wilbon, S. S., & Kolonin, M. G. (2023) · Cells · doi:10.3390/cells13010065 · Cited by 101
Malavazos, A. E., Iacobellis, G., Dozio, E., Basilico, S., Di Vincenzo, A., Dubini, C., Menicanti, L., Vianello, E., Meregalli, C., Ruocco, C., et al. (2023) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwad050 · Cited by 100
Targeting the incretin system in obesity and type 2 diabetes mellitus
Ansari, S., Khoo, B. C. E., & Tan, T. (2024) · Nature Reviews Endocrinology · doi:10.1038/s41574-024-00979-9 · Cited by 127
Gut hormone co-agonists for the treatment of obesity: from bench to bedside
Nogueiras, R., Nauck, M. A., & Tschöp, M. H. (2023) · Nature Metabolism · doi:10.1038/s42255-023-00812-z · Cited by 102
Muzurović, E. M., Volčanšek, Š., Zibar, K., Janež, A., Mikhailidis, D. P., Rizzo, M., & Mantzoros, C. S. (2022) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/10742484221146371 · Cited by 125
“001 for all).(139) In addition, approximately 8% of patients treated with semaglutide (1 mg OW SC) achieved a BW loss of 15%, compared with 15%, 24%, and 36% of patients treated with tirzepatide at doses of 5, 10, and 15 mg, respectively.”
BackgroundInfluentialHankosky, E. R., Wang, H., Neff, L. M., Kan, H., Wang, F., Ahmad, N. N., Griffin, R., Stefanski, A., & Garvey, W. T. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15318 · Cited by 97
Vosoughi, K., Atieh, J., Khanna, L., Khoshbin, K., Prokop, L. J., Davitkov, P., Murad, M. H., & Camilleri, M. (2021) · eClinicalMedicine · doi:10.1016/j.eclinm.2021.101213 · Cited by 97
“In the future, comparison of selective GLP-1 agonists or analogs with dual glucose-stimulated insulinotropic peptide agonist, tirzepatide, will be of significant interest, given a recent report [94] of greater weight loss with 10 and 15 mg SQ tirzepatide weekly in comparison to 1mg SQ semaglutide weekly in patients wi…”
BackgroundTirzepatide induces a thermogenic-like amino acid signature in brown adipose tissue
Samms, R. J., Zhang, G., He, W., Ilkayeva, O., Droz, B. A., Bauer, S. M., Stutsman, C., Pirro, V., Collins, K. A., Furber, E. C., et al. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101550 · Cited by 93
“Objectives: Tirzepatide, a dual GIP and GLP-1 receptor agonist, delivered superior glycemic control and weight loss compared to selective GLP-1 receptor (GLP-1R) agonism in patients with type 2 diabetes (T2D).”
ResultInfluentialAbushamat, L. A., Shah, P. A., Eckel, R. H., Harrison, S. A., & Barb, D. (2024) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2024.01.032 · Cited by 92
Cardiorenal diseases in type 2 diabetes mellitus: clinical trials and real-world practice
Lim, L.-L., Chow, E., & Chan, J. C. N. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00776-2 · Cited by 91
le Roux, C. W., Zhang, S., Aronne, L. J., Kushner, R. F., Chao, A. M., Machineni, S., Dunn, J., Chigutsa, F. B., Ahmad, N. N., & Bunck, M. C. (2023) · Obesity · doi:10.1002/oby.23612 · Cited by 91
Ciardullo, S., Muraca, E., Vergani, M., Invernizzi, P., & Perseghin, G. (2023) · Gastroenterology report · doi:10.1093/gastro/goae029 · Cited by 121
Glucagon-like peptide-1 receptor agonist use in pregnancy: a review
Drummond, R. F., Seif, K. E., & Reece, E. A. (2024) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2024.08.024 · Cited by 113
Min, J. S., Jo, S. J., Lee, S., Kim, D. Y., Kim, D. H., Lee, C. B., & Bae, S. K. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s506957 · Cited by 132
Ndumele, C. E., Rodriguez, F., Dixon, D. L., Khan, S. S., Mukherjee, D., Bajaj, M., Bangalore, S., Bozkurt, B., Breathett, K., Clarke, S. L., et al. (2026) · JACC · doi:10.1016/j.jacc.2026.03.056 · Cited by 90
Tobaiqy, M., & Elkout, H. (2024) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-023-01694-7 · Cited by 88
Malhotra, A., Bednarik, J., Chakladar, S., Dunn, J. P., Weaver, T., Grunstein, R., Fietze, I., Redline, S., Azarbarzin, A., Sands, S. A., et al. (2024) · Contemporary Clinical Trials · doi:10.1016/j.cct.2024.107516 · Cited by 92
Glucose-dependent insulinotropic polypeptide (GIP)
Müller, T. D., Adriaenssens, A. E., Ahrén, B., Blüher, M., Birkenfeld, A. L., Campbell, J. E., Coghlan, M. P., D’Alessio, D. D., Deacon, C. F., DelPrato, S., et al. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2025.102118 · Cited by 112
Obesity Treatment With Bariatric Surgery vs GLP-1 Receptor Agonists
Barrett, T. S., Hafermann, J. O., Richards, S., LeJeune, K., & Eid, G. M. (2025) · JAMA Surgery · doi:10.1001/jamasurg.2025.3590 · Cited by 87
Zhang, B., Cheng, Z., Chen, J., Zhang, X., Liu, D., Jiang, H., Ma, G., Wang, X., Gan, S., Sun, J., et al. (2024) · Diabetes Care · doi:10.2337/dc23-1287 · Cited by 91
Inflammatory Trajectory of Type 2 Diabetes: Novel Opportunities for Early and Late Treatment
Pellegrini, V., Grotta, R. L., Carreras, F., Giuliani, A., Sabbatinelli, J., Olivieri, F., Berra, C., Ceriello, A., & Prattichizzo, F. (2024) · Cells · doi:10.3390/cells13191662 · Cited by 117
Semaglutide and cancer: A systematic review and meta-analysis
Nagendra, L., BG, H., Sharma, M., & Dutta, D. (2023) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2023.102834 · Cited by 86
Tan, B., Pan, X.-H., Chew, H. S. J., Goh, R. S. J., Lin, C., Anand, V. V., Lee, E. C. Z., Chan, K. E., Kong, G., Ong, C. E. Y., et al. (2023) · International Journal of Obesity · doi:10.1038/s41366-023-01321-5 · Cited by 83
Mesinovic, J., Fyfe, J. J., Talevski, J., Wheeler, M. J., Leung, G. K. W., George, E. S., Hunegnaw, M. T., Glavas, C., Jansons, P., Daly, R. M., et al. (2023) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2023.0112 · Cited by 114
“In a recent head-to-head study, tirzepatide led to greater reductions in body mass and HbA1c compared with semaglutide in individuals with T2DM, although the semaglutide dose was 1 mg (once-weekly) [193].”
BackgroundRosen, C. J., & Ingelfinger, J. R. (2026) · New England Journal of Medicine · doi:10.1056/nejmra2500106 · Cited by 135
Gallwitz, B. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1004044 · Cited by 81
“In the SURPASS-2 study, the three doses of tirzepatide (5, 10, and 15 mg once weekly) were tested with the GLP-1RA semaglutide (1 mg once weekly) as a comparator in patients not optimally controlled on monotherapy with metformin (71).”
BackgroundMethodResultInfluentialPipek, L. Z., Moraes, W. A. F., Nobetani, R. M., Cortez, V. S., Condi, A. S., Taba, J. V., Nascimento, R. F. V., Suzuki, M. O., do Nascimento, F. S., de Mattos, V. C., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-57724-5 · Cited by 80
“Finally, choosing the most appropriate treatment often involves individual characteristics of each patient, and the impact on quality of life can be extremely subjective and difficult to assess.”
BackgroundAdriaenssens, A., Broichhagen, J., de Bray, A., Ast, J., Hasib, A., Jones, B., Tomas, A., Burgos, N. F., Woodward, O., Lewis, J., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.164921 · Cited by 77
“(C) sGIP549, sGIP648, and native GIP(1-42) cAMP signaling responses in T-REx-SNAP-GIPR cells, n = 3.”
Understanding the cause of type 2 diabetes
Taylor, R. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00157-8 · Cited by 95
Romeo, S., Vidal‐Puig, A., Husain, M., Ahima, R. S., Arca, M., Bhatt, D. L., Diehl, A. M., Fontana, L., Foo, R., Frühbeck, G., et al. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf314 · Cited by 108
Advances in the management of type 2 diabetes in adults
Galindo, R. J., Trujillo, J. M., Wang, C. C. L., & McCoy, R. G. (2023) · BMJ Medicine · doi:10.1136/bmjmed-2022-000372 · Cited by 109
The incretin/glucagon system as a target for pharmacotherapy of obesity
Del Prato, S., Gallwitz, B., Holst, J. J., & Meier, J. J. (2022) · Obesity Reviews · doi:10.1111/obr.13372 · Cited by 77
“ing bodyweight in patients with T2DM at all tested doses (5, 10, or 15 mg), with 34%–57% of patients receiving tirzepatide experiencing bodyweight reductions of ≥10%, compared with 24% of those receiving semaglutide (1 mg).(132) In the Phase III SURPASS-3 trial of”
BackgroundEnteroendocrine cell regulation of the gut-brain axis
Barton, J. R., Londregan, A., Alexander, T. D., Entezari, A. A., Covarrubias, M., & Waldman, S. A. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1272955 · Cited by 102
Moon, J. S., Hong, J. H., Jung, Y. J., Ferrannini, E., Nauck, M. A., & Lim, S. K. (2022) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2022.03.005 · Cited by 85
Moon, J. S., Kang, S., Choi, J. H., Lee, K. A., Moon, J. H., Chon, S., Kim, D. J., Kim, H. J., Seo, J. A., Kim, M. K., et al. (2024) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2024.0249 · Cited by 90
Liu, Q., Zhu, J., Kong, B., Shuai, W., & Huang, H. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110311 · Cited by 81
Qin, W., Yang, J., Deng, C., Ruan, Q., & Duan, K. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15386 · Cited by 72
Papamargaritis, D., le Roux, C. W., Holst, J. J., & Davies, M. J. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvac176 · Cited by 73
“83,121 Tirzepatide is a once weekly unimolecular agonist of both GLP-1 and GIP receptors which has a deliberate bias towards GIP over GLP-1 activity (it possesses five-fold increased relative potency at human GIP receptor when compared with GLP-1 receptor).”
BackgroundInfluentialSelf-citationPan, X., Tan, B., Chin, Y. H., Lee, E. C. Z., Kong, G., Chong, B., Kueh, M., Khoo, C. M., Mehta, A., Majety, P., et al. (2024) · Obesity · doi:10.1002/oby.24002 · Cited by 71
Lakhani, M., Kwan, A. T. H., Mihalache, A., Popovic, M. M., Nanji, K., Xie, J. S., Feo, A., Rabinovitch, D., Shor, R., Sadda, S., et al. (2025) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2025.05.007 · Cited by 70
Jeong, B.-K., Choi, W., Choi, W., Moon, J., Lee, W. H., Choi, C., Choi, I. Y., Lee, S.-H., Kim, P., Ju, Y. S., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-50660-y · Cited by 90
“While tirzepatide is an effective treatment for T2DM and obesity 14 – 16 with signi fi cant promise as a therapeutic option for MASLD 17 , its potential long-term bene fi ts in preventing the progression to advanced fi brosis or HCC are unknown.”
GLP-1 agonist to treat obesity and prevent cardiovascular disease: what have we achieved so far
Pedrosa, M. R., Franco, D. R., Gieremek, H. W., Vidal, C. M., Bronzeri, F., de Cassia Rocha, A., de Carvalho Cara, L. G., Fogo, S. L., & Eliaschewitz, F. G. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01062-2 · Cited by 68
Bays, H. E., Fitch, A., Christensen, S., Burridge, K., & Tondt, J. (2022) · Obesity Pillars · doi:10.1016/j.obpill.2022.100018 · Cited by 68
Zeng, Q., Xu, J., Mu, X., Shi, Y., Fan, H., & Li, S. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1214334 · Cited by 66
Tirzepatide prevents neurodegeneration through multiple molecular pathways
Fontanella, R. A., Ghosh, P., Pesapane, A., Taktaz, F., Puocci, A., Franzese, M., Feliciano, M. F., Tortorella, G., Scisciola, L., Sommella, E., et al. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-04927-z · Cited by 67
“A novel drug, TIR has been recently synthesized, able to bind both GLP-1 and GIP incretin receptors and with a stronger effect in decreasing glycated hemoglobin and in improving systemic insulin sensitivity in T2DM, when compared to the GLP-1RA [14, 17].”
BackgroundYu, X., Chen, S., Funcke, J.-B., Straub, L. G., Pirro, V., Emont, M. P., Droz, B. A., Collins, K. A., Joung, C., Pearson, M. J., et al. (2025) · Cell Metabolism · doi:10.1016/j.cmet.2024.11.003 · Cited by 67
Le, R., Nguyen, M. T., Allahwala, M. A., Psaltis, J. P., Marathe, C. S., Marathe, J. A., & Psaltis, P. J. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13164674 · Cited by 66
“Tirzepatide, a novel ‘twincretin’ targeting both GLP-1 and GIP receptors, has demonstrated efficacy for treating T2DM in the SURPASS clinical trial program [168] and overweight/obesity in the SURMOUNT studies [169].”
BackgroundPrevention of cardiorenal complications in people with type 2 diabetes and obesity
Drucker, D. J. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2023.12.018 · Cited by 67
Garvey, W. T. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2021.11.082 · Cited by 66
Semaglutide and Tirzepatide in Patients With Heart Failure With Preserved Ejection Fraction
Krüger, N., Schneeweiss, S., Fuse, K., Matseyko, S., Sreedhara, S. K., Hahn, G., Schunkert, H., & Wang, S. V. (2025) · JAMA · doi:10.1001/jama.2025.14092 · Cited by 66
Tirzepatide and prevention of chronic kidney disease
Bosch, C., Carriazo, S., Soler, M. J., Ortiz, A., & Fernandez-Fernandez, B. (2023) · Clinical Kidney Journal · doi:10.1093/ckj/sfac274 · Cited by 60
“per week semaglutide for both weight loss and glycemic control in patients with T2DM [12].”
Background2022 FDA TIDES (Peptides and Oligonucleotides) Harvest
Musaimi, O. A., Shaer, D. A., Alberício, F., & de la Torre, B. G. (2023) · Pharmaceuticals · doi:10.3390/ph16030336 · Cited by 71
“It is worth highlighting that the same adverse effects, to the same extent, have been observed in patients who received semaglutide [30].”
BackgroundKarakasis, P., Patoulias, D., Fragakis, N., Klisic, A., & Rizzo, M. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15410 · Cited by 65
Ji, L., Jiang, H., An, P., Deng, H., Liu, M., Li, L., Feng, L., Song, B., Han-Zhang, H., Ma, Q., et al. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.101088 · Cited by 63
“5% at week 12 in adults with type 2 diabetes[23].”
BackgroundDual GIP/GLP-1 receptor agonists: new advances for treating type-2 diabetes
Scheen, A. J. (2023) · Annales d'Endocrinologie · doi:10.1016/j.ando.2022.12.423 · Cited by 63
When fat meets the gut—focus on intestinal lipid handling in metabolic health and disease
Wit, M., Viera, J. T., Strohmeyer, A., Klingenspor, M., Hankir, M. K., & Sumara, G. (2022) · EMBO Molecular Medicine · doi:10.15252/emmm.202114742 · Cited by 73
GIP reduces osteoclast activity and improves osteoblast survival in primary human bone cells
Hansen, M. S., Søe, K., Christensen, L. L., Fernandez-Guerra, P., Hansen, N. W., Wyatt, R. A., Martin, C., Hardy, R. S., Andersen, T. L., Olesen, J. B., et al. (2023) · European Journal of Endocrinology · doi:10.1093/ejendo/lvac004 · Cited by 62
“…remains to be studied in clinical studies if these observed changes are maintained with long-term GIPR agonism, drugs targeting GIPR, including tirzepatide, 56-58 could represent a new class of anti-osteoporotic therapeutics with long-term advantages over currently approved anti-resorptive drugs.”
BackgroundA Comprehensive Review on Weight Loss Associated with Anti-Diabetic Medications
Haddad, F., Dokmak, G., Bader, M., & Karaman, R. (2023) · Life · doi:10.3390/life13041012 · Cited by 79
Drake, T. C., Landsteiner, A. M. K., Langsetmo, L., MacDonald, R. H., Anthony, M., Kalinowski, C., Ullman, K. E., Billington, C. J., Kaka, A. S., Sultan, S., et al. (2024) · Annals of Internal Medicine · doi:10.7326/m23-1490 · Cited by 74
Taktaz, F., Fontanella, R. A., Scisciola, L., Pesapane, A., Basilicata, M. G., Ghosh, P., Franzese, M., Tortorella, G., Puocci, A., Vietri, M. T., et al. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02319-7 · Cited by 72
“In all SURPASS programs, tirzepatide demonstrated a much greater HbA1c-lowering impact than placebo or active comparators, such as basal insulin and GLP1RAs [83, 86].”
BackgroundMethodBajaj, M. S., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Early, K. B., ChallaSivaKanaka, S., Echouffo-Tcheugui, J. B., et al. (2025) · Diabetes Care · doi:10.2337/dc26-s008 · Cited by 165
Dual and Triple Incretin-Based Co-agonists: Novel Therapeutics for Obesity and Diabetes
Gutgesell, R. M., Nogueiras, R., Tschöp, M. H., & Müller, T. D. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01566-x · Cited by 61
“Critically, the most frequent adverse events with tirzepa-tide, mild to moderate gastrointestinal events, including vomiting (5–10%), diarrhea (12–16%), and nausea (17–22%), were not higher than semaglutide in SUPRASS-2 [97].”
BackgroundCho, Y. K., Lee, Y. L., & Jung, C. H. (2023) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2023.12.3.213 · Cited by 71
Feier, C., Vonica, R., Faur, A., Streinu, D., & Muntean, C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25084346 · Cited by 60
Dutta, D., Surana, V., Singla, R., Aggarwal, S., & Sharma, M. (2021) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_423_21 · Cited by 60
“Since papers by Pirro et al.,[18] Wilson et al.,[6] Hartman et al.,[19] and Thomas et al.[20] were post‑hoc analysis of original RCT by Frias et al.[12](2018); in our analysis, the results from these four papers have been pooled with data from Frias et al. (2018) to avoid duplicity.”
BackgroundMethodInfluentialWeight loss efficiency and safety of tirzepatide: A Systematic review
Lin, F., Yu, B., Ling, B., Lv, G., Shang, H., Zhao, X., Jie, X., Chen, J., & Li, Y. (2023) · PLOS ONE · doi:10.1371/journal.pone.0285197 · Cited by 60
GLP-1 receptor agonists in patients with chronic kidney disease and either overweight or obesity
Abasheva, D., Ortíz, A., & Fernández‐Fernández, B. (2024) · Clinical Kidney Journal · doi:10.1093/ckj/sfae296 · Cited by 70
de Mesquita, Y. L. L., Pera Calvi, I., Reis Marques, I., Almeida Cruz, S., Padrao, E. M. H., Carvalho, P. E. D. P., da Silva, C. H. A., Cardoso, R., Moura, F. A., & Rafalskiy, V. V. (2023) · International Journal of Obesity · doi:10.1038/s41366-023-01337-x · Cited by 59
“We adopted a conservative approach and assumed that 25% of people in the tirzepatide group, including any dose (from 5mg to 15mg), would achieve a 10% weight loss versus 10% in the placebo group [24].”
MethodRecent advances in the treatment of type 2 diabetes mellitus using new drug therapies
Chong, K., Chang, J. K.-J., & Chuang, L. (2024) · The Kaohsiung Journal of Medical Sciences · doi:10.1002/kjm2.12800 · Cited by 84
Bhagavathula, A. S., Vidyasagar, K., & Tesfaye, W. (2021) · Pharmaceuticals · doi:10.3390/ph14100991 · Cited by 58
“, 2021 [20] NCT03987919 (SURPASS-2) USA, UK, Argentina, Australia, Brazil, Canada, Israel, Mexico Multicenter, phase 3, open-label, parallel-group, randomized, active-controlled T2DM for at least 6 months ([HbA1c] 7.”
BackgroundChao, A. M., Tronieri, J. S., Amaro, A., & Wadden, T. A. (2022) · Drug Design, Development and Therapy · doi:10.2147/dddt.s365416 · Cited by 58
“9% of initial weight loss(91) and even greater weight losses than semaglutide.(92) Tirzepatide is being tested in the phase 3 SURMOUNT clinical trial program.”
BackgroundMotta, B. M., Masarone, M., Torre, P., & Persico, M. (2023) · Cancers · doi:10.3390/cancers15225458 · Cited by 66
Akturk, H. K., Dong, F., Snell-Bergeon, J. K., Karakus, K. E., & Shah, V. N. (2025) · Journal of Diabetes Science and Technology · doi:10.1177/19322968231223991 · Cited by 58
Lingvay, I., Mosenzon, O., Brown, K., Cui, X., O’Neill, C., Fernández Landó, L., & Patel, H. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01797-5 · Cited by 55
“There was no significant difference between tirzepatide and semaglutide in the SURPASS-2 study at Week 40 in change in heart rate compared to baseline despite higher reduction in HbA1c, weight and SBP [18].”
BackgroundSelf-citationTherapeutic advances in obesity management: an overview of the therapeutic interventions
Roomy, M. A., Hussain, K., Behbehani, H. M., Abu-Farha, J., Al-Harris, R., Ambi, A. M., Abdalla, M. A., Al‐Mulla, F., Abu‐Farha, M., & Abubaker, J. A. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1364503 · Cited by 78
Metadata
- Authors
- Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K.
- Affiliations
- University of Leicester (GB)
- From the National Research Institute, Los Angeles (J.P.F.); the Diabetes Research Centre, University of Leicester, and the National Institute of Health Research Leicester Biomedical Research Centre — both in Leicester, United Kingdom (M.J.D.); the Dallas Diabetes Research Center at Medical City, Dallas (J.R.); Centro de Investigaciones Metabólicas, Buenos Aires (F.C.P.M.); and Eli Lilly, Indianapolis (L.F.L., B.K.B., B.L., X.C., K.B.).
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-08-05
- Volume
- 385
- Issue
- 6
- Pages
- 503-515
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3177122952
- Cited by
- 2,096
- References
- 25
- Citations by year
- 2026: 526 · 2025: 556 · 2024: 396 · 2023: 351 · 2022: 208 · 2021: 57
- FWCI
- 188.92
- Type
- journal article
- Language
- en
- Open access
- green
- figshare.com
- Licence
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Figshare (submittedVersion, cc-by)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- semaglutide, type 2 diabetes, HbA1c, GLP-1 receptor agonists, GIP/GLP-1 dual agonist, non-inferiority, weight loss, gastrointestinal adverse effects, drug safety, dose comparison, glycemic control, adverse drug reactions, hypoglycemia
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Tirzepatide, Semaglutide, Blood Glucose, Diabetes Mellitus, Type 2, Dose-Response Relationship, Drug, Drug Administration Schedule, Drug Therapy, Combination, Glucagon-Like Peptides, Female, Gastric Inhibitory Polypeptide, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Injections, Subcutaneous, Male, Metformin, Middle Aged, Nausea, Weight Loss, Incretins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.